Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
1.310
-0.100 (-7.04%)
Nov 5, 2024, 11:13 AM EST - Market open
Barinthus Biotherapeutics Revenue
In the year 2023, Barinthus Biotherapeutics had annual revenue of $802.00K, down -98.21%.
Revenue (ttm)
$802.00K
Revenue Growth
-98.21%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
130
Market Cap
51.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 802.00K | -43.90M | -98.21% |
| Dec 31, 2022 | 44.70M | 44.44M | 16,580.22% |
| Dec 31, 2021 | 268.00K | -4.55M | -94.44% |
| Dec 31, 2020 | 4.82M | -2.02M | -29.57% |
| Dec 31, 2019 | 6.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Theratechnologies | 84.32M |
| DIH Holding US | 67.62M |
| Atara Biotherapeutics | 62.39M |
| Cryo-Cell International | 31.84M |
| Prenetics Global | 22.66M |
| Aligos Therapeutics | 7.97M |
| VolitionRx | 976.52K |
BRNS News
- 5 months ago - Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewsWire
- 5 months ago - Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B - GlobeNewsWire
- 6 months ago - Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments - GlobeNewsWire
- 6 months ago - Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer - GlobeNewsWire
- 7 months ago - Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - GlobeNewsWire
- 8 months ago - Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments - GlobeNewsWire
- 10 months ago - Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - GlobeNewsWire
- 11 months ago - New partnership aims to advance vaccine against MERS coronavirus - GlobeNewsWire